Net Present Value Model: Yervoy
Powered by
Unlock hidden opportunities in the NPV industry
Overview
Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis.
Drug Operating Profit Model
Yervoy Drug Details
Ipilimumab (Yervoy, Winglore) is a recombinant, human monoclonal antibody belongs to antineoplastic agent. It is formulated as solution, powder for solution and concentrate solution for intravenous route of administration. It is indicated for the treatment of unresectable or metastatic melanoma. Yervoy also used as adjuvant therapy for patients with stage III melanoma, to lower the risk that the melanoma will return following surgery. Yervoy in combination with opdivo (nivolumab) is indicated for the treatment of unresectable or metastatic melanoma in previously untreated adults. It is also indicated for the treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years of age and older, and nivolumab (Opdivo) in combination with ipilimumab (Yervoy), as first-line treatment for patients with metastatic non-small cell lung cancer whose tumors express PD-L1(=1%), as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, and also nivolumab in combination with ipilimumab ( and 2 cycles of platinum-doublet chemotherapy as first-line treatment for patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. YERVOY, in combination with nivolumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. Yervoy in combination with nivolumab, is indicated for the treatment of unresectable or metastatic melanoma in adult patients. Yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer.The drug candidate is under development for the treatment of chronic lymphocytic leukemia (CLL), homologous-recombination deficient (HRD) metastatic adenocarcinoma of the pancreas, Richter transformation (RT), relapsed/refractory multiple myeloma, metastatic neuroendocrine prostate cancer (NEPC), metastatic advanced uveal melanoma, neurofibromatosis type 1 (NF1), malignant peripheral nerve sheath tumors (MPNST), metastatic urothelial carcinoma, metastatic renal cell carcinoma, cutaneous melanoma, glioblastoma multiforme (GBM), gliosarcoma, Merkel cell carcinoma, diffuse large B cell lymphoma, solid tumors including liver cancer, lung cancer and adrenal gland cancer, chronic myelocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, Hodgkin lymphoma, acute myelocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome and chronic lymphocytic leukemia. Yervoy in combination with Opdivo is indicated for the first-line treatment of unresectable, advanced or recurrent esophageal cancer in adults. Yervoy in combination with Opdivo as a first-line treatment for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC).It was also under development for transitional cell cancer (urothelial cell cancer, breast cancer, adenocarcinoma, squamous non-small cell lung cancer, metastatic prostate cancer (as a first line therapy), metastatic hormone refractory (castration-resistant, androgen-independent) prostate cancer, ovarian cancer and melanoma. It was under development for the treatment of human immunodeficiency virus (HIV) infection.
Report Coverage
GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
Quick View – Retifanlimab NPV Data | |||
Drug Name |
|
||
Administration Pathway |
|
||
Therapeutic Areas |
|
||
Key Manufacturers |
|
||
Drug Development Status |
|
Reasons to Buy
- Better understand the quantitative value of a specific drug
- Create or support internal NPV models to improve accuracy
- Understand the profit a drug is expected to make, taking into account revenue and cost forecasts leveraging public and proprietary data sets.
Frequently asked questions
- All drug sales and forecasts within NPV Model are calculated in our proprietary company based models . In these models, Analyst Consensus forecasts are built by using company-specific broker reports to create the sales forecasts for each Drug and Segment.
- Sales and forecasts are not indication-specific where drugs are approved , or in development, for multiple indications. Please refer to GlobalData’s Disease Analysis reports for indication-specific sales forecasts.
- Risk-adjusted NPVs use GlobalData’s LoA and PTSR for the indication in the highest development stage. Please refer to the Likelihood of Approval methodology for more details on this content.
GlobalData’s NPV Model is a premium model providing a fully-interactive forecasting and valuation tool, driven by Analyst Consensus estimates, enabling users to analyze and customize valuations for pharmaceutical assets including drugs or segments. The tool provides 17-year drug forecasts from companies with sales forecast data in the pharmaceutical industry, including established global firms and emerging biotechs, which allows access to critical information to facilitate strategic decision making around pharmaceutical assets
The NPV Model includes a forecasted Revenue Model, followed by a proprietary Patent Expiry Model, Operating Profit Model, Net Profit (apply Tax rate) and Discounted Cash Flow (apply Discount rates), to derive Net Present Value (NPV) for a chosen pharmaceutical asset
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.